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Abstract
The neuraminidase (NA) inhibitor (NAI) oseltamivir (OST) is the most widely used influenza
antiviral drug. Several NA amino acid substitutions are reported to reduce viral susceptibility
to OST in in vitro assays. However, whether there is a correlation between the level of reduc-
tion in susceptibility in vitro and the efficacy of OST against these viruses in vivo is not well
understood. In this study, a ferret model was utilised to evaluate OST efficacy against circu-
lating influenza A and B viruses with a range of in vitro generated 50% inhibitory concentra-
tions (IC50) values for OST. OST efficacy against an A(H1N1)pdm09 and an A(H1N1)
pdm09 virus with the H275Y substitution in neuraminidase was also tested in the macaque
model. The results from this study showed that OST had a significant impact on virological
parameters compared to placebo treatment of ferrets infected with wild-type influenza A
viruses with normal IC50 values (~1 nM). However, this efficacy was lower against wild-type
influenza B and other viruses with higher IC50 values. Differing pathogenicity of the viruses
made evaluation of clinical parameters difficult, although some effect of OST in reducing
clinical signs was observed with influenza A(H1N1) and A(H1N1)pdm09 (H275Y) viruses.
Viral titres in macaques were too low to draw conclusive results. Analysis of the ferret data
revealed a correlation between IC50 and OST efficacy in reducing viral shedding but
highlighted that the current WHO guidelines/criteria for defining normal, reduced or highly
reduced inhibition in influenza B viruses based on in vitro data are not well aligned with the
low in vivo OST efficacy observed for both wild-type influenza B viruses and those with
reduced OST susceptibility.
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Author summary
Oseltamivir (Tamiflu) is an antiviral widely used for the treatment of infection due to
influenza viruses and is especially useful for the treatment of severely ill high-risk patients.
Antiviral resistance to oseltamivir is of concern as it can undermine the utility of the drug.
Influenza viruses can become less susceptible to oseltamivir due to amino acid substitu-
tions that arise in the viral surface protein, neuraminidase (NA). During influenza surveil-
lance, to monitor for resistance, laboratory experiments are carried out to measure viral
susceptibility to oseltamivir, whereby the quantity of drug needed to inhibit NA enzyme
action is measured. However, how well these laboratory measurements predict resistance
of viruses to oseltamivir in a clinical setting is not well understood. In this study, we devel-
oped an animal model to evaluate this relationship between laboratory data and clinical
efficacy in more detail and demonstrated that in vivo efficacy of oseltamivir is lower
against viruses that show reduced inhibition by oseltamivir in laboratory testing. A key
finding from our analysis was that oseltamivir had reduced efficacy in reducing viral shed-
ding against wild-type influenza B viruses compared to wild-type influenza A viruses,
which has implications on how data from influenza B viruses with reduced susceptibility
are currently being interpreted.
Introduction
Infection with influenza viruses results in a highly contagious respiratory disease that causes
substantial global morbidity and mortality [1]. Antivirals play a major role in the treatment
and prophylaxis against influenza infections and neuraminidase inhibitors (NAIs) remains the
most commonly used antiviral [2, 3]. NAIs are sialic acid analogues that target the viral neur-
aminidase (NA) protein and competitively inhibit enzyme activity by blocking the NA active
site [4, 5]. While there are four NAIs currently available (zanamivir, oseltamivir (OST), lanina-
mivir and peramivir [6–8]), OST is the most commonly prescribed antiviral globally, due to its
ease of oral administration [9].
Resistance or reduced susceptibility to OST can arise due to amino acid substitutions in the
NA active site or the region surrounding the active site, that can lead to reduced drug binding
[10–17]. However, the overall proportion of circulating influenza viruses with reduced OST
susceptibility has generally remained relatively low (below 2%), since the drug’s licensure in
1999 [10–17]. The only exception was during the 2007–2009, when a former seasonal influenza
A(H1N1) virus with the H275Y NA amino acid substitution circulated world-wide and led to
guideline changes against the use of OST [18, 19]. The emergence of this virus underscored the
importance of maintaining regular surveillance of influenza viruses to monitor antiviral sus-
ceptibility [10–13, 20]. However, fortuitously, this virus was replaced during the 2009 pan-
demic with an OST sensitive swine-origin A(H1N1)pdm09 virus [21, 22], lacking the H275Y
substitution. While community outbreaks have also occurred since 2009 with H275Y A
(H1N1)pdm09 viruses [23, 24], the overall prevalence of H275Y in this subtype has generally
remained low.
Susceptibility of viruses to OST is typically determined using an in vitro NA enzyme inhibi-
tion assay to measure the 50% inhibitory concentration (IC50) of the drug, which is then used
to infer if a virus has reduced susceptibility or not [25, 26]. While this assay is a quick, high
throughput and convenient way to analyse viral isolates, early studies differed in their classifi-
cation of viruses based on IC50 values [14, 25, 27]. To improve reporting of viruses with
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reduced susceptibility, a criteria was standardised in 2012 by the WHO working group on
influenza antiviral susceptibility (WHO-AVWG) [28], such that influenza A viruses with a 10–
100 fold increase in OST IC50 compared to a susceptible human influenza virus of the same
NA subtype were described to have ‘reduced inhibition’, while those with greater than a
100-fold increase in OST IC50 were described as having ‘highly reduced inhibition’. The equiv-
alent fold-differences for influenza B viruses were set to 5–50 fold for ‘reduced inhibition’ and
greater than 50-fold for ‘highly reduced inhibition’, due to wild-type influenza B viruses having
higher baseline OST IC50 values than influenza A viruses [28]. However, this classification sys-
tem was relatively arbitrary with thresholds set to help coordinate reporting of in vitro enzy-
matic assay data between different laboratories, rather than having any clinical relevance. As
such there has been no agreement or studies on how these in vitro IC50 values relate to OST
treatments in vivo, against human influenza viruses with reduced susceptibility.
There are only a few examples where the clinical effectiveness of OST against viruses with
increased OST IC50 values have been evaluated. In a Japanese multicentre study during the
2008–2009 influenza season, OST was administered to patients prior to knowing that the
infecting virus contained the H275Y NA substitution with a highly increased OST IC50 [29].
Analysis of the clinical data showed that OST-treated patients infected with viruses bearing the
H275Y substitution had increased fever duration compared to OST-treated patients infected
with wild-type A(H1N1) viruses [29].Two other studies in Japan, also demonstrated reduced
benefit of OST treatment in children infected with the influenza A(H1N1) (H275Y) virus,
compared to those infected with the wild-type A(H1N1) viruses [30, 31]. There are also limited
examples from two cases of immunocompromised patients infected with influenza A(H3N2)
viruses bearing the E119V NA substitution with an increased IC50, whereby a rebound in viral
load was observed following the emergence of this virus, despite continued OST treatment [32,
33]. Finally, a number of clinical studies have shown that OST is less effective in reducing
symptoms in patients infected with wild-type influenza B viruses, which have higher average
OST IC50 values, compared to patients infected with wild-type influenza A viruses [14, 34–39].
Although these ad-hoc case studies demonstrate that the efficacy of OST is reduced or lost
against some viruses with increased OST IC50 values, the magnitude of the change is not clear
and many clinical studies are confounded by underlying health aspects of the patients, such as
being immunocompromised, which are likely to reduce antiviral efficacy. Therefore, our aim
in this study was to assess the efficacy of OST against a range of wild-type and reduced suscep-
tibility seasonal influenza viruses with varying IC50 values in different animal models and
establish a relationship between the in vitro IC50 data and the in vivo OST efficacy.
We focussed initially on the ferret model because unlike many other animal models, ferrets
can be infected directly with human influenza viruses and exhibit clinical signs similar to those
displayed by humans [40–44]. Due to the lack of a reduction in the virus load seen in previous
studies with OST in ferrets ‘artificially’ infected with a large intranasal dose of virus [45–47],
we utilised a model of ‘natural’ infection whereby ferrets were infected by exposure to an
experimentally infected donor, similar to the way in which humans are naturally infected by
influenza. We further carried out a pilot experiment, testing OST efficacy in macaques infected
with either a wild-type or reduced susceptibility virus. While viral replication in macaques was
poor and did not produce conclusive results, we were able to evaluate the effect of OST dosing
on viral shedding and clinical signs in ferrets infected with either wild-type or reduced suscep-
tibility viruses, and showed a loss of OST efficacy (based on viral shedding), against viruses
with increased IC50 values.
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Materials and Methods
Viruses
Wild-type viruses (lacking known amino acid substitutions in the NA drug binding region)
with typically low IC50 values were used in this study, including; an A(H1N1) pdm09 virus (A/
Perth/265/2009), a former seasonal wildtype clone of an A(H1N1) virus (A/Mississippi/3/
2001), an A(H3N2) virus (A/Fukui/20/2004), and an influenza B virus from the B-Yamagata
lineage (B/Minnesota/23/2015). These viruses are referred to as H1N1, H1N1pdm09, H3N2
and B respectively, hereafter in this report. The viruses with reduced susceptibility (viruses
containing NA substitutions known to increase OST IC50 values) were an A(H1N1)pdm09
virus with the H275Y NA substitution (A/Perth/261/2009), a clone of a former seasonal A
(H1N1) virus with the H275Y NA substitution (A/Mississippi/3/2001), an A(H3N2) virus with
the E119V NA substitution (A/Fukui/45/2004) and two influenza B viruses from the B-Yama-
gata lineage, one with the H273Y NA substitution (B/Perth/265/2015), and the other with the
D197N NA substitution (B/Singapore/GP702/2015). These viruses are referred to as
H1N1pdm09 (H275Y), H1N1 (H275Y), H3N2 (E119V), B (H273Y) and B (D197N) respec-
tively hereafter.
All viruses were collected as part of the World Health Organization Global Influenza Sur-
veillance and Response System (GISRS) or kindly provided by the Centers for Disease Control
and Prevention (CDC), Atlanta, United States and the National Institute of Infectious Disease
(NIID), Tokyo, Japan. The viruses were cultured in Madin-Darby canine kidney (MDCK;
ATCC CCL-34) cells at 35˚C, 5% CO2 in Dulbecco’s modified Eagle Media (DMEM; SAFC-
Bioscience, Lenexa, KS, USA) supplemented with 200 mM L-glutamine, 100X MEM non-
essential amino acid solution, 7.5% sodium bicarbonate, 1M HEPES buffer solution, penicil-
lin-streptomycin solution, 2 mg/ml fungizone and 4 μg/mL of TPCK-trypsin (all from Sigma-
Aldrich, Castle Hill, NSW, Australia). The infectivity titre of the viruses was quantified via
viral infectivity assay and a 50% tissue culture infectious dose (TCID50) calculated as described
by Reed and Muench [48]. The haemagglutinin (HA) and NA genes of all viruses were
sequenced, and their susceptibility phenotype assessed by NAI susceptibility assay as described
below.
Fluorometric NA inhibition assay
A fluorescence-based assay utilising the substrate 2’-(4-methylumbelliferyl)-a-D-N-acetylneur-
aminic acid (MUNANA; Sigma-Aldrich, Castle Hill, NSW, Australia) was used to measure the
enzymatic activity and the relative inhibition of enzyme activity by oseltamivir carboxylate
(Carbosynth, UK) using methods described previously [26]. The NAI concentration that
inhibited 50% of NA activity (IC50) was determined using JASPR (version 1.2, CDC, USA)
software program.
Ethics statement
Experiments using ferrets were conducted with the approval of Melbourne University Animal
Ethics Committee (project license number 1313040) in strict accordance with the Australian
Government, National Health and Medical Research Council Australian code of practice for
the care and use of animals for scientific purposes (8th edition). Ferret studies were conducted
at the Bio-Resources Facility located at the Peter Doherty Institute. The experiments with
Cynomolgus macaques (Macaca fascicularis) were approved by the SingHealth Institutional
Animal Care and Use Committee of the Sing Health Experimental Medicine Centre (SEMC
IACUC Reference: 2014/SHS/922).
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Ferrets
Outbred approximately 6-month-old adult male and female ferrets (Animalactic Animals &
Animal Products Pty Ltd, Victoria, Australia) weighing 608–1769 g were used. Serum samples
from ferrets were tested by hemagglutination inhibition assay to ensure seronegativity against
currently circulating influenza A subtypes and B-lineages. Ferrets were housed in high effi-
ciency particulate air filtered cages with ab libitum access to food, water and enrichment
equipment throughout the experimental period. Ferrets were randomly allocated to experi-
mental groups.
Model setup for evaluating oseltamivir efficacy
An outline for the experimental model used in this study is illustrated in S1 Fig. Ferrets were
dosed orally with 5 mg/kg dose of oseltamivir phosphate (kindly provided by F. Hoffmann-La
Roche AG, Basel, Switzerland) twice a day, which is considered equivalent to the standard
treatment human adult dose of 75 mg/kg delivered twice daily [49]. Oseltamivir phosphate
solution was prepared at a concentration of 10 mg/mL in a sterile 0.5% sugar/phosphate buff-
ered saline (PBS) solution, while a placebo solution was prepared containing only sterile 0.5%
sugar/PBS solution. On Day 1 naïve test ferrets were orally delivered either 5 mg/kg of OST or
placebo and after 2 hours were exposed to an experimentally infected donor. The donors were
experimentally infected on Day 0 with 500 μL of 1 x 106 TCID50 of virus as previously
described [50]. The test ferrets were dosed again with either OST or placebo 8 hours post first
dose and twice daily for the next 10 days. Daily nasal washes were collected from the test ferrets
and activity, weight and temperature monitoring were carried out each day at approximately
the same time in the morning.
This experimental model was utilised to evaluate OST efficacy against nine different viruses,
with the only variation in protocol being the exposure time of test ferrets to donors. Test ferrets
exposed to H1N1-infected donors were co-housed for 48 hours, while those exposed to
H3N2-infected ferrets were co-housed for a maximum of 6 days and ferrets exposed to influ-
enza B-infected donors were co-housed for 11 days. The difference in length of co-housing
was informed by previous pilot experiments that demonstrated a difference in time of trans-
mission for each type/subtype. At the end of the experiment, ferrets were euthanized by
administration of anaesthetic by intramuscular injection [50:50 mix of Ilium Xylazil (Xylazine,
20 mg/mL): Ketamine (100 mg/mL)] followed by an overdose of pentobarbitone sodium
(Lethabarb, 0.5 mL/kg) (Virbac, Australia). Cardiac bleeds were taken for serological analysis
by hemagglutination inhibition assay.
Ferret monitoring, activity measurement and sample collection
All animal measurements were collected in a blinded manner. Activity levels of the ferrets
were determined by video-monitoring, and body temperature and weight were measured
daily at approximately the same time points as previously described [50]. Nasal washes were
collected daily from sedated ferrets (intramuscular injection of Xylazine at 5 mg/kg) by
instilling 1 mL of sterile PBS into one nostril and allowing the liquid to flow out of the other
nostril into a collection tube. The number of viable cells in the nasal washes was counted
immediately after collection. Aliquots of nasal washes were stored at -80˚C with 0.01% of
bovine serum albumin for determining viral titres or -20˚C prior to determining protein
concentrations.
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Inflammatory cell and protein concentration, virological and sequencing
analysis
Viable cells in the ferret nasal washes were determined by Trypan blue exclusion using a
Countess automated cell counter (Life technologies, Carlsbad, CA, USA). Protein concentra-
tion in the nasal washes were determined using Coomassie Plus (Bradford assay) according to
manufacturer’s instructions (ThermoFisher scientific, Scoresby, Victoria, Australia). Titres of
infectious virus in the nasal washes were quantified by a viral infectivity assay and a TCID50
calculated as described by Reed and Muench [48], with a minimal detection limit of 102
TCID50/ml. Next generation sequencing was performed on nasal washes from peak shedding
day from each ferret, to ensure the genetic stability of the NA gene in viruses post-transmission
and following replication in ferrets, as described previously [51]. Briefly, viral RNA was
extracted using QIAamp Viral RNA kit (Qiagen, Germany) and influenza genes were ampli-
fied utilising previously described primers for influenza B viruses [52] and influenza A viruses
[53]. Next Generation Sequencing (NGS) was done off-site on the Illumina MiSeq platform.
NGS reads were mapped to their respective genome using Bowtie2 [54] and percentage of sin-
gle nucleotide polymorphism (SNPs) estimated utilising Vascan2 [55].
Evaluating OST efficacy in macaques
Oseltamivir efficacy against the H1N1pdm09 and H1N1pdm09 (H275Y) viruses was also
evaluated in a macaque model of infection. Cynomolgus macaques were purchased from the
SingHealth colony and were free of antibodies against influenza as determined by immunoper-
oxidase monolayer assay [56]. The animals were group housed until the beginning of the
experiment. During the experiment, animals were housed individually to accurately assess
clinical signs and disease severity in each animal. Cages were positioned to ensure visual con-
tact with other animals. Toys were provided for enrichment and rotated at least every week.
Food was provided ad libitum and fruits offered as treats.
Starting the day before infection and daily throughout the study, animals were anesthetized
by intramuscular injection with ketamine (10 mg/kg) and then intubated to collect throat and
nasal swabs and to perform nasal and tracheal lavages. Anaesthesia was maintained with iso-
flurane as needed. The day before infection, a pill-size temperature sensor was given by pill
applicator to record the body temperature every 15 min. If this sensor was excreted during the
study, it was reapplied the following morning during anaesthesia. For the infection, three ani-
mals per group were infected via the intra-tracheal route with 4x106 TCID50/ml. Animals were
treated with 3 mg/kg OST (Tamiflu suspension, Roche) or an equal volume of fruit juice orally,
starting a day prior to infection and continued for four days after. The macaques were
observed daily for activity and clinical signs. Each time the animals were anaesthetized, body
temperature was also measured rectally and the weight recorded. Viral titre in the different
samples was quantified by the TCID50 assay, and next generation sequence analysis was carried
out on Day 4 tracheal lavage samples, as previously described [51]. At the completion of the
experiment, a necropsy was performed on each animal. Anaesthesia was followed by pentobar-
bital (85mg/kg) overdose through IV catheter. Death was verified and confirmed by an SEMC/
NLARF veterinarian prior to necropsy.
Statistical analysis
A non-parametric Wilcoxon rank-sum test was used to compare each individual metric: viral
titre, length of viral shedding, activity, cell-count, protein concentration, weight and tempera-
ture, between ferrets/macaques in the placebo and OST group, for each day. Area under the
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curve (AUC) was calculated for viral titre and clinical symptoms in Graphpad prism 6.0. Dif-
ference in AUC for viral titre or symptoms between placebo and OST dosed ferrets was stan-
dardized to total AUC of the placebo dosed animals for each virus, and the spearman
correlation was calculated between % differences in AUC (%ΔAUC) to IC50 values. The rela-
tionship between %ΔAUC difference in viral shedding and IC50 values were further explored
by fitting different linear and non-linear models in R software [57], and the model with the
lowest Akaike information criterion (AIC) value was selected. The fitted curve was plotted on
R and bootstrapping was used to calculate 95% confidence intervals.
Results
The effect of OST dosing on viral shedding in the upper respiratory tract of ferrets was evalu-
ated by measuring a number of parameters, including a) number of infected ferrets, b) peak
viral loads in the nasal wash, c) duration of viral shedding and d) area under curve of viral
shedding curves (Table 1). The clinical signs evaluated during the experiments included mea-
suring changes in body weight, temperature and activity, and cell counts and total protein con-
centration in nasal washes, as indicators of nasal inflammation. Changes in each clinical sign
were assigned scores as shown in Table 2, which was then used to calculate a total clinical
score for each test group (Table 3).
Oseltamivir efficacy in ferrets infected with the H1N1 or H1N1(H275Y)
virus
OST was effective in preventing infectious virus shedding in all H1N1 exposed ferrets tested
(0/4 infected), while 3/4 (75%) of the placebo dosed animals shed infectious virus for an aver-
age duration of 5.7 days (Fig 1, Table 1). The animals that did not shed infectious virus also
remained seronegative for H1N1 (S1 Table).
Reductions in clinical signs were also apparent, with the placebo dosed ferrets that became
infected with the H1N1 virus experiencing >50% loss in activity, whereas the OST dosed
Table 1. The IC50 values of infecting viruses and viral shedding characteristics of ferrets dosed with either placebo or oseltamivir.
Influenza Virus IC50
#$ (fold difference)a % Ferrets Infected (no.) Peak Viral Titre#$ Duration of Shedding$ AUC#B
Placebo OST Placebo OST Placebo OST Placebo OST
Influenza A
H1N1 0.9 ± 0.4 75 (3/4) 0 (0/4) 4.4 ± 0.2 N/A 5.7±1.1 0.0 ± 0.0� 17.2 ± 12.3 0.0 ± 0.0�
H1N1 (H275Y) 414.8 ± 46.2 (460) 100 (4/4) 100 (4/4) 4.8 ± 0.6 4.6± 0.5 4.8±0.5 5.2±1.25 16.9 ± 0.7 18.2 ± 4.3
H1N1pdm09 0.3 ± 0.2 100 (4/4) 50 (2/4) 4.8 ± 0.7 4.2 ± 0.9 4.8±0.5 3.5±0.7 18.6 ± 2.9 9.3 ± 12.7
H1N1pdm09 (H275Y) 192.0 ± 46.9 (640) 100 (4/4) 100 (4/4) 5.5 ± 0.4 5.2 ± 0.6 6.5±1.7 6.0±1.4 24.6 ± 5.5 23.4 ± 4.4
H3N2 0.2 ± 0.1 100 (7/7) 50 (4/8) 4.4 ± 0.4 3.0 ± 0.8� 5.0±0.6 2.0±0.8� 14.4 ± 1.8 3.0 ± 3.7�
H3N2 (E119V) 65.6 ± 28.9 (328) 62 (5/8) 62 (5/8) 4.7 ± 0.9 4.8 ± 0.4 4.0±1.6 3.8±0.5 7.9 ± 7.0 6.0 ± 7.7
Influenza B
B 36.1 ± 5.4 100 (4/4) 100 (4/4) 4.7 ± 0.9 3.7 ± 0.4 4.8±1.0 5.5±0.6 19.8 ± 4.0 12.9 ± 1.9
B (D197N) 66.2 ± 7.5 (2) 75 (6/8) 100 (4/4) 4.4 ± 0.8 4.5 ± 0.5 5.5±0.5 4.2±1.0 11.5 ± 6.9 12.6 ± 2.3
B (H273Y) 96.7 ± 10.8 (3) 100 (4/4) 100 (4/4) 4.2 ± 0.7 3.8 ± 0.6 4.0±1.1 5.2±0.5 11.3 ± 2.1 13.5 ± 1.0
# Data is presented in the following format where possible: Mean ± Standard Deviation
$ IC50 unit is nM, Viral titre unit is Log10 TCID50/ml, Duration of shedding is days, and no unit for AUC
�A significant difference is observed between placebo and OST (Wilcoxon rank-sum test) dosed ferrets
a Fold difference of each reduced susceptibility virus is calculated in comparison to corresponding wild-type.
b Total area under the curve of raw data, therefore no adjustments were made for uninfected ferrets or varying days of first infection
https://doi.org/10.1371/journal.ppat.1008592.t001
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ferrets, who remained uninfected, had activity levels that fluctuated around pre-exposure base-
line levels (S3 Fig). The difference in weight loss and nasal inflammation was also notable, with
the difference in %AUC for weight, cell count and protein concentration being 2.5%, 67% and
74% respectively, and significant differences were observed in nasal inflammation indicators
on Day 2 (S5 and S6 Figs). In contrast, OST was less effective against the H1N1 (H275Y) virus
as all ferrets shed infectious virus, regardless of treatment group assigned. The clinical signs of
the H1N1(H275Y) infected ferrets were somewhat improved due to OST (Table 3), and reduc-
tion in protein concentration in the nasal wash was significant on Day 4 (S6 Fig).
Oseltamivir efficacy in ferrets infected with the H1N1pdm09 or
H1N1pdm09 (H275Y) virus
Only 50% (2/4) of the OST dosed ferrets exposed to the H1N1pdm09 virus had detectable
virus in their nasal washes, while all placebo dosed ferrets (4/4) became infected (Table 1). Of
the two OST dosed ferrets that did not shed H1N1pdm09 virus, one developed a low HAI titre
of 40, while the other remained seronegative (S1 Table). Amongst the ferrets that became
infected, peak viral titres were similar between OST and placebo dosed animals (4.2±0.9 Log10
TCID50/ml vs. 4.8±0.7 Log10 TCID50/ml), however, on average, placebo dosed animals shed
virus for a day longer (4.8±0.5 days), compared to OST dosed animals (3.5±0.7 days) (Table 1).
The overall clinical score was substantially improved due to the OST dosing, with improve-
ments seen across all parameters measured (Table 3), and significant differences observed in
Table 2. The clinical score card used to determine severity of clinical signs in ferrets infected with influenza viruses.
Score % Weight loss from baseline#� % Activity loss from baseline#� Temperature increase from baseline#� Nasal inflammation indicators�
Protein concentration# Cell count#
0 Weight increase or no change �20 <1 <500 <1X106
1 1–3 21–40 1.1–1.5 500–1000 1 to 2 x106
2 3–6 41–60 1.5–2.0 1001–1500 2.1 to 4 x106
3 >6 >60 >2.0 >1500 >4x106
�maximum values considered i.e. maximum weight loss, activity loss, protein concentration, etc
# Weight loss and Activity loss are measured as % change from baseline, temperature measured in
 
C, protein content measured in μg/ml and cell count in cells/ml
https://doi.org/10.1371/journal.ppat.1008592.t002
Table 3. Severity of clinical signs in ferrets infected with influenza viruses.
Virus Weight loss Activity loss Temperature Nasal inflammation Total Score
Protein Cell
Placebo OST Placebo OST Placebo OST Placebo OST Placebo OST Placebo OST
Influenza A
H1N1 1 0 3 1 1 1 3 0 2 1 10 3
H1N1(H275Y) 1 1 2 3 3 2 2 0 1 1 9 7
H1N1pdm09 3 0 3 1 3 2 3 2 3 1 15 6
H1N1pdm09(H275Y) 3 3 3 3 3 3 3 3 3 3 15 15
H3N2 0 0 1 1 0 0 1 0 2 0 4 1
H3N2(E119V) 0 0 0 0 0 0 0 0 0 0 0 0
Influenza B
B 0 0 1 1 2 0 1 1 0 1 3 3
B(D197N) 0 0 1 1 0 0 2 0 1 0 4 1
B(H273Y) 0 0 1 1 0 0 0 0 0 0 1 1
https://doi.org/10.1371/journal.ppat.1008592.t003
PLOS PATHOGENS Determining oseltamivir efficacy in animal models
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008592 June 18, 2020 8 / 20
weight change, protein concentration and activity levels on Day 4 (S4–S6 Figs), with differ-
ences in %AUC being 4.9%, 56% and 53%, respectively. In ferrets exposed to the H1N1pdm09
(H275Y) virus, OST dosing had little benefit compared to placebo, as all virological parameters
and clinical score remained similar between OST dosed and placebo dosed animals.
Oseltamivir efficacy in ferrets infected with the H3N2 or H3N2 (E119V)
virus
OST was effective at preventing 4/8 (50%) ferrets from shedding infectious virus following
exposure to the H3N2 virus, whereas all exposed placebo ferrets (7/7) shed detectable virus
(Table 1). Of note, the four OST dosed animals that did not shed infectious virus, nevertheless
seroconverted with HI titres ranging between 80–160 (S1 Table). The OST dosed ferrets that
became infected with the H3N2 virus had a significantly lower peak viral titre (4.4±0.4 Log10
TCID50/ml vs. 3.0±0.8 Log10 TCID50/ml) and duration of viral shedding (5.0±0.6 vs 2.0±0.8
days) than placebo dosed ferrets (Fig 1, Table 1). The magnitude of clinical signs in ferrets
infected with the H3N2 viruses was lower than those ferrets infected with either the H1N1 or
H1N1pdm09 virus (Table 3). As such the efficacy of OST on weight, activity or temperature
change in ferrets infected with the H3N2 virus was minimal (Table 3). However, OST dosing
did reduce nasal inflammation in H3N2 infected ferrets, with significant differences in cell
counts observed on most days (S5 Fig), and significant difference in protein concentrations
observed on Day 7 and 8 (S6 Fig). The %AUC for cell counts and protein concentration were
reduced by 69.2% and 52.4% respectively.
Similar to previous results, OST efficacy in preventing or reducing viral shedding was lost
against the H3N2 virus with the E119V substitution, and clinical signs overall were minimal,
making comparisons between groups difficult.
Oseltamivir efficacy in ferrets infected with the influenza B, B (D197N) or
B (H24Y) virus
Although OST was ineffective at preventing infection in ferrets exposed to the B virus, peak
viral titre and AUC tended to be lower in the OST dosed ferrets compared to placebo dosed
ferrets, although it wasn’t significantly different (Table 1). Due to the short timeframe of the
experiment (10 days), influenza B infected animals did not seroconvert (but may have if tested
later). Clinical signs were very also mild in ferrets infected with the B viruses and no notable
OST effect was observed on activity, weight, temperature or nasal inflammation (Table 3).
Similar to wild-type B virus, OST dosing did not reduce infection rates in ferrets exposed to
either B(D197N) or B(H273Y) viruses. Comparison of viral titres between placebo and OST
dosed ferrets across each day also revealed no significant differences, except for a single day
when OST dosed ferrets infected with the B (D197N) virus shed viruses at a significantly
higher titre (4.1 ± 0.4 Log10 TCID50/ml) than their placebo counterparts (2.5 ± 1.3 Log10
TCID50/ml). Clinical signs were also mild in B(D197N) or B(H273Y) infected ferrets. No dif-
ference in activity, weight, and cell count were observed between ferrets infected with the B
(H273Y) virus dosed with either OST or placebo (S3–S5 Figs). Ferrets infected with the B
(D197N) virus did not experience any weight loss, and activity was similar between OST and
placebo ferrets (S3 and S4 Figs). However, cell counts and protein concentrations were gener-
ally higher in the nasal washes of ferrets infected with the B (D197N) virus and dosed with pla-
cebo, with a significant difference in protein concentrations observed on Day 7 (S6 Fig,
Table 3).
Genetic analysis of nasal washes revealed some changes in the HA and NA genes of the all
the test viruses, summarised in detail in S2 Table (S2 Table). However, none of the genetic
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changes in the NA were in the active site or have been previously associated with reduced sus-
ceptibility to OST.
Correlating the in vitro IC50 values with the in vivo effects of oseltamivir
The IC50 values calculated from a neuraminidase inhibition assay, measures OST’s capacity to
inhibit the enzymatic activity of the influenza NA protein. It was our aim to correlate values
from this in vitro assay with a more biologically relevant metric. The relative change in Area
Under the Curve in viral shedding curves (%ΔAUC), comparing placebo dosed and OST
dosed animals, was chosen as such a metric, as it summarises key virological parameters
including peak viral titres, infection rate, and duration of viral shedding in the one measure-
ment. Fig 2 reveals a non-linear relationship between IC50 and %ΔAUC of viral shedding, with
a Spearman correlation coefficient of -0.81 (p = 0.017). This non-linear regression model
could then be used to estimate that an IC50 of 14.6 nM, corresponded to a 50% reduction in
OST efficacy and an IC50 of 68.2 nM corresponded to a 90% loss in oseltamivir efficacy against
viral shedding. Effectiveness of OST in recovering activity trended with IC50 values although
Spearman’s rho was only -0.48 and not significant (p = 0.194). A significant correlation (rho =
-0.7, p = 0.043) between weight changes and IC50 values was observed. However, a %ΔAUC in
weight change was observed even when placebo animals did not lose weight, due to the weight
gain of their OST counterparts, and as such this correlation does not truly reflect OST’s effect
in recovering weight loss. Temperature, cell count and protein concentration were not well
correlated with IC50 values (spearman rhos were -0.1, -0.41 and -0.18 respectively).
OST efficacy in macaques
To evaluate if the findings in ferrets would also be observed in an animal model that has more
similar lung physiology and drug metabolism to that of humans, a macaque model of infection
was used [58, 59]. Animals were infected with either the H1N1pdm09 virus or the
H1N1pdm09 (H275Y) virus and OST dosing was compared to placebo. In this study, the
macaques did not develop any clinical signs, and there were no significant differences in body
weight or temperature between OST- and placebo-treated animals. Viral titres in nasal wash
and tracheal lavages were low (ranging between 103−105 TCID50/ml) and not significantly dif-
ferent between placebo and OST dosed macaques (Fig 3). It should be noted however that, in
animals infected with the H1N1pdm09 virus, viral titres were 1.9 logs lower in the tracheal
lavages of OST dosed macaques compared to placebo animals, on Day 3 post-infection. A sim-
ilar phenomenon was not observed in animals infected with the H1N1pdm09(H275Y) virus.
Sequence analysis of viruses recovered from the tracheal lavage did not indicate reversion
of the H275Y substitution in NA and only minor changes in the rest of the NA and HA genes
(S2 Table).
Discussion
In this study the efficacy of OST was evaluated in the ferret model against nine different influ-
enza viruses with OST IC50 values ranging from 0.2–414 nM. OST efficacy was evaluated
based on assessment of virological parameters and clinical signs of infection. We were able to
show that OST was effective in reducing viral shedding in the upper respiratory tract of ferrets
Fig 1. Viral shedding data from ferrets exposed to different viruses and dosed with either OST or Placebo. The data for all ferrets are
shown after standardising to first day of TCID50 positive, as this day varied between different ferrets, and each individual ferret within a
group is identified by a separate colour. The variability in first day of viral shedding is summarised in S2 Fig. The bar graphs represent the
mean viral titre for all ferrets within the group on each day. The B stands for baseline.
https://doi.org/10.1371/journal.ppat.1008592.g001
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infected with influenza A wild-type viruses. However, this drug effect was reduced in animals
infected with wild-type influenza B virus and influenza A or B viruses with increased IC50
levels.
This study also aimed to investigate the efficacy of OST in a macaque model challenged
with an A(H1N1)pdm09 wild type or a H275Y bearing virus. However, a lack of clinical symp-
toms and lower virus titres in respiratory samples made it difficult to show any significant
reductions with OST. Previous studies have shown that the clinical signs of A(H1N1)pdm09
virus infection in macaques can be dependent on virus strains [60–62]. It is therefore impor-
tant to further develop the macaque model of OST treatment, possibly using different viral
strains, to reach a more conclusive result regarding efficacy. While the conclusions from this
part of the study are limited, this data adds to the small pool of literature available on NAI effi-
cacy in the macaque influenza challenge model [63–67].
In this study, we were able to establish a significant correlation between in vitro generated
OST IC50 values and the efficacy of OST in reducing viral shedding in vivo in ferrets. We
found that IC50 can be a strong predictor of OST efficacy, regardless of virus background. For
example, the viral replication of the H3N2(E119V) and the B(D197N) viruses, which had simi-
lar IC50 values (ranging between 65-66nM), were similarly impacted by OST treatment.
Fig 2. A scatter plot showing the relationship between %ΔAUC (difference between placebo and OST dosed animals) of viral shedding of ferrets and the
OST IC50. This graph shows the significant correlation between in vitro OST IC50 and in vivo effect on viral shedding. The regression model reveals the
following relationship where y = e4.35–0.03x. The shaded region of the graph is the 95% confidence interval of the line of best fit, calculated by bootstrapping
over 2500 iterations.
https://doi.org/10.1371/journal.ppat.1008592.g002
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Fig 3. Influenza virus titres from nasal washes and tracheal lavages from macaques infected with either H1N1pdm09 or H1N1pdm09 (H275Y) virus
and treated with either OST or placebo. Three macaques were allocated per group and artificially infected with 106 TICD50/ml of viral inoculum. No
significant differences were observed in viral titre between animals treated with OST compared to those treated with placebo. Panel a) shows viral titre data
from nasal washes of animals and b) shows viral tire data from tracheal lavages.
https://doi.org/10.1371/journal.ppat.1008592.g003
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OST was less effective in reducing the severity of clinical signs in ferrets infected with wild-
type influenza B virus, compared to those infected with wild-type influenza A viruses, although
this was in part due to the clinical signs from the influenza B infection being milder than those
with the influenza A viruses. A number of clinical trials have also shown OST treatment to be
less effective in reducing symptom duration and severity in patients infected with influenza B
viruses compared to those infected with influenza A viruses [34–39, 68]. Our finding, com-
bined with these previous results, provides increased evidence that OST has reduced efficacy
against wild-type influenza B viruses. This has implications for how influenza B viruses with
reduced drug susceptibility are defined and understood. For example, the influenza B (H273Y)
virus in this study has a 3-fold increase in IC50 compared to its corresponding wild-type, and
under the current WHO guidelines would be classified as having ‘normal inhibition’, even
though our study shows that OST efficacy in reducing viral shedding of this virus was lower
than that of wild-type influenza B. These findings suggest that the WHO criteria for defining
influenza B viruses with ‘reduced’ or ‘highly reduced inhibition’ may need to be revisited.
However more human clinical data needs to be collected regarding OST efficacy against influ-
enza B viruses with reduced in vitro susceptibility before a decision on any new criteria should
be made.
A limitation of the model is that different viruses confer different pathogenicity in ferrets,
which makes evaluating OST efficacy based on clinical signs more difficult. The clinical score
for infection was lower for H3N2 and B infections than H1N1 or H1N1pdm09 infections,
making it more difficult to evaluate OST efficacy against these viruses. Viruses with reduced
NAI susceptibility can also exhibit reduced pathogenicity which can make evaluating the clini-
cal effect of antiviral treatment against these viruses challenging. Whilst this study demon-
strated that the mild clinical signs in untreated ferrets resulted in insufficient capacity to detect
an effect of OST, the effect of OST treatment was able to elicit a strong correlation between
viral shedding and OST IC50. Host factors, such as ferret immunity (they are naïve to influ-
enza), are an additional caveat to the analysis in this study, further exacerbated by small ferret
numbers (ranging between 4–8 animals/group), which limits the power of statistical analysis.
While improving the power of this study would be desirable, the use of larger animal cohorts is
prohibitively expensive, and insights derived from small group sizes of n = 4 animal numbers
have previously provided valuable insights [40, 43, 45, 69–75]. Finally, another limitation of
this study is that the results observed in ferrets and macaques may not directly align with those
seen in humans, as they not only have physiological differences but in most cases (apart from
small infants) humans have some level of prior immunity to influenza [40, 41, 43, 45, 69–76].
However even with these limitations, data from animal models remains very useful, and have
been previously used to gain valuable insights into influenza virus biology and antiviral efficacy
[40, 41, 43, 45, 69–76].
The ferret treatment model used in this study involved the initiation of OST prior to influ-
enza infection, whereas antiviral treatment in humans is typically initiated 24 to 48 hours after
infection or onset of symptoms. In addition, in the ferret model dosing was maintained for 10
days as opposed to 5 days in the typical human situation [77]. We have previously conducted
studies to evaluate the effect of OST when it was initiated 12 or 24-hours post-exposure but lit-
tle or no virological effect was observed making that protocol unsuitable for testing of OST
[47]. To optimise the virological effect of oseltamivir in the ferret, we modified the model such
that ferrets were infected by exposure to an infected donor, instead of direct intranasal inocula-
tion. This method has the drawback that the exact time of infection for each ferret is unknown.
Therefore, dosing was standardized to start 2-hours prior to exposure for all animals, and as
some animals became influenza virus positive late in the experiment (Day 6 or 7, S1 Fig), dos-
ing was continued throughout the full length of the experiment (10 days). Therefore, whilst the
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dosing regimen used in the ferrets differs from the standard human treatment regimen, it was
necessary to change these aspects to achieve a ferret model where an OST effect was observed
allowing subsequent evaluation of the impact of OST on viruses with reduced susceptibility.
In summary, we investigated the relationship between in vitro IC50 and in vivo efficacy of
OST in two complementary animal models. While data from the macaque model was not con-
clusive, we were able to show in ferrets that OST was less effective in reducing viral shedding
against viruses with higher IC50 values than wild-type viruses. It should be noted that while
IC50 was shown to be an important predictive measure, viral pathogenicity, and immunologi-
cal factors can also play a role in OST efficacy. This study is the first to quantitatively illustrate
how OST efficacy correlates to the increased IC50 of human influenza viruses, and highlights
the need to re-evaluate the current guidelines for defining ‘normal’, ‘reduced’ or ‘highly
reduced’ inhibition for influenza B viruses, although further human clinical studies and analy-
sis are needed to establish more relevant levels.
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